Edition:
India

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

11.00USD
20 Apr 2018
Change (% chg)

$-0.22 (-2.00%)
Prev Close
$11.23
Open
$11.15
Day's High
$11.15
Day's Low
$10.50
Volume
256,774
Avg. Vol
97,413
52-wk High
$29.00
52-wk Low
$10.50

Select another date:

Thu, Apr 19 2018

BRIEF-Paratek Pharmaceuticals Prices $140 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. PRICES $140 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

BRIEF-Paratek Appoints Rolf Hoffman To Co's Board Of Directors

* PARATEK APPOINTS ROLF K. HOFFMAN TO COMPANY’S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA

* PARATEK’S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA

BRIEF-Paratek Pharmaceuticals Reports Q4 Loss Per Share $0.78

* PARATEK PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REMAINS ON TRACK FOR COMMERCIAL LAUNCH BY FIRST QUARTER 2019

BRIEF-Paratek Completes Submission Of New Drug Applications To U.S.FDA

* PARATEK COMPLETES SUBMISSION OF NEW DRUG APPLICATIONS TO U.S. FOOD AND DRUG ADMINISTRATION FOR ORAL AND INTRAVENOUS OMADACYCLINE FOR PNEUMONIA AND SKIN INFECTIONS Source text for Eikon: Further company coverage:

BRIEF-Paratek Announces $50.0 Mln Public Offering Of Common Stock

* PARATEK PHARMACEUTICALS INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS SHARES OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Paratek Provides Update On Pipeline Progress

* PARATEK PHARMACEUTICALS - HAS EARNED A $5 MILLION MILESTONE PAYMENT FROM ALLERGAN FOR DEVELOPMENT OF SEYSARA Source text for Eikon: Further company coverage:

BRIEF-Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln

* PARATEK PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING‍​ Source text (http://bit.ly/2BqNSiB) Further company coverage:

BRIEF-Paratek Pharmaceuticals Q3 loss per share $0.77

* Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018

Select another date: